Bravera Wealth’s Edwards Lifesciences EW Stock Holding History

Bravera Wealth’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7	Closed	-$597	–	443
2025 Q4	$597	Buy	+7	New	+$574	﹤0.01%	475

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bravera Wealth's EW Position: Q1 2026 in Review

Bravera Wealth sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 7 shares — an estimated $597 sold.

Bravera Wealth first reported a position in EW in Q4 2025 and held it in 1 quarter. The position peaked at $597 in Q4 2025. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Bravera Wealth reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
Bravera Wealth sold 7 Edwards Lifesciences shares in Q1 2026, an estimated $597.
Bravera Wealth first reported a position in Edwards Lifesciences in Q4 2025 and held it in 1 quarter.
Bravera Wealth's Edwards Lifesciences position peaked at $597 in Q4 2025.
1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Bravera Wealth's 13F filing for Q1 2026, filed 22 Apr 2026.